Four new clinical trial updates touch on semaglutide this week, and together they point to where GLP-1 drugs may be headed next. None of these represent a new FDA approval or access change today. But the questions they're asking, about kidney protection and drug comparisons, could shape future insurance coverage decisions. If you take a GLP-1 medication or are considering one, it helps to understand what these trials are actually testing, and what they are not.
Chronic kidney disease is common among people with type 2 diabetes, and doctors have long looked for ways to slow its progression. Finerenone is a drug already used to protect the kidneys in diabetic patients, and this trial asked whether adding semaglutide to that treatment does more than finerenone alone. The study has finished, and researchers are now analyzing results that should be public soon. If the combination shows a real benefit, it could give physicians a new reason to prescribe semaglutide to patients whose main concern is kidney health, rather than weight or blood sugar alone. That would be a notable shift in how insurers evaluate the drug's use.
Ozempic, Mounjaro, and Zepbound are all weekly injections, but they work through slightly different mechanisms and have not been directly compared in one large trial until now. This phase 3 study enrolled both diabetic and non-diabetic patients to measure weight loss and metabolic effects across all three drugs at once. Enrollment has closed, and the trial is complete, so results are now a matter of when they are published rather than if. Head-to-head data like this is rare, and it could give patients and doctors clearer guidance on which drug fits a given health profile. Insurers may also use these findings to decide which GLP-1 they prefer to cover first.
Endometrial cancer treatment usually involves surgery that removes the uterus, which ends a patient's ability to have children. For women with early-stage, grade 1 endometrial cancer or atypical hyperplasia who want to preserve fertility, this trial offers a different approach. It pairs semaglutide and a weight loss program with an LNG-IUD, a hormone-releasing device already used to treat some early endometrial conditions. The trial has not yet begun recruiting patients, so results are a long way off, but the design reflects growing interest in whether weight loss itself can support cancer treatment outcomes. This is one to watch rather than one to act on now.
This trial uses carbon-13 MRI to study how the brain and heart process lactate in people with type 2 diabetes. It has not yet started recruiting, and it does not involve a GLP-1 drug directly, so it will not affect what your insurance covers or what your doctor can prescribe. It is included here because diabetes research often overlaps with GLP-1 treatment in ways that can be confusing to follow. Readers who take a GLP-1 medication for diabetes do not need to track this study closely unless they are also interested in metabolic research for its own sake.
None of these four trials will change what a GLP-1 prescription costs or covers today. But the kidney and drug-comparison studies are close enough to completion that their results could influence coverage decisions within the next year or two. If you rely on semaglutide or a similar medication, it is reasonable to ask your doctor whether new kidney-related data might apply to your case, especially if you also manage chronic kidney disease. Keep an eye on this tracker for when those results are published, and talk to your care team before making any changes based on early trial news.
Key details
Semaglutide plus finerenone finished testing for kidney protection, with results due soon.
Three weekly GLP-1 drugs are being compared in a completed phase 3 study, results pending.
This trial will test semaglutide with an IUD and weight loss for early endometrial cancer.
A separate diabetes study on brain and heart health is not an FDA action on GLP-1 access.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.